MLTX
MoonLake Immunotherapeutics
Key Financials
Net Income
$-227318000
↓ 91.1%
Total Liabilities
$120.0M
↑ 388.8%
Total Assets
$424.4M
↓ 11.2%
Shareholders' Equity
$304.5M
↓ 31.9%
EPS (Diluted)
$-3.53
↓ 86.8%
Cash & Equivalents
$334.5M
↑ 85.4%
Long-term Debt
$74.1M
↑ Infinity%
Operating Income
$-244834000
↓ 71.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/16/2026 | View on SEC |
| 4 | 4/14/2026 | View on SEC |
| 4 | 4/10/2026 | View on SEC |
| 144 | 4/10/2026 | View on SEC |
| 144 | 4/9/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| SCHEDULE 13D/A | 4/2/2026 | View on SEC |
| 144 | 3/31/2026 | View on SEC |
| 10-K | 2/25/2026 | View on SEC |
| 8-K | 2/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MLTX |
| Company Name | MoonLake Immunotherapeutics |
| CIK | 1821586 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | E9 |
| Phone | 41 41 510 8022 |